Recent News
Watch the Video to Learn More
Partnering Opportunities
Our technologies enable us to rapidly develop novel immunotherapies against targets of interest with potential partners.
Our Lead Programs
Kleo is rapidly advancing multiple candidates against a range of hematological and solid tumors
Partnering Opportunities
Our technologies enable us to rapidly develop novel immunotherapies against targets of interest with potential partners.
Our Lead Programs
Kleo is rapidly advancing multiple candidates against a range of hematological and solid tumors
Our Technologies
News
NEW HAVEN, Conn., Dec. 2, 2019 /PRNewswire/ — Kleo Pharmaceuticals, Inc., an immuno-oncology company developing next-generation, fully synthetic bispecific compounds […] Read More
New Haven, CT, Oct. 15, 2019 – Kleo Pharmaceuticals Inc., a unique immuno-oncology company developing next-generation bispecific compounds designed to […] Read More
In 2012, five years before he became the CSO of Bristol-Myers Squibb, Thomas Lynch began hearing from a Yale colleague […] Read More
Events
Biotech Showcase
